Clinical characteristics of nateglinide response as assessed by insulinogenic indices: Preliminary study to determine an optimal indication for nateglinideMORI, Yutaka; ISHII, Hirotaka; HIKITA, Miho et al.Advances in therapy. 2003, Vol 20, Num 6, pp 352-359, issn 0741-238X, 8 p.Article

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinideKALLIOKOSKI, Annikka; BACKMAN, Janne T; NEUVONEN, Pertti J et al.Pharmacogenetics and genomics (Print). 2008, Vol 18, Num 11, pp 937-942, issn 1744-6872, 6 p.Article

Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinideWEI ZHANG; HE, Yi-Jing; HU, Dong-Li et al.British journal of clinical pharmacology. 2006, Vol 62, Num 5, pp 567-572, issn 0306-5251, 6 p.Article

Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjectsSABIA, Helene; SUNKARA, Gangadhar; LIGUEROS-SAYLAN, Monica et al.European journal of clinical pharmacology. 2004, Vol 60, Num 6, pp 407-412, issn 0031-6970, 6 p.Article

Improvement of insulin resistance by a new insulin secretagogue, nateglinide: analysis based on the homeostasis modelSHIBA, Teruo.Diabetes research and clinical practice. 2003, Vol 62, Num 2, pp 87-94, issn 0168-8227, 8 p.Article

Thermodynamic relationships between nateglinide polymorphsBRUNI, G; BERBENNI, V; MILANESE, C et al.Journal of pharmaceutical and biomedical analysis. 2009, Vol 50, Num 5, pp 764-770, issn 0731-7085, 7 p.Article

A validated stability indicating LC method for nateglinidePATHARE, D. B; JADHAV, A. S; SHINGARE, M. S et al.Drug development and industrial pharmacy. 2007, Vol 33, Num 5, pp 551-557, issn 0363-9045, 7 p.Article

Nateglinide quantification in rabbit plasma by HPLC : Optimization and application to pharmacokinetic studySANKALIA, Jolly M; SANKALIA, Mayur G; SUTARIYA, Vijay B et al.Journal of pharmaceutical and biomedical analysis. 2007, Vol 44, Num 1, pp 196-204, issn 0731-7085, 9 p.Article

Acute and long-term effects of nateglinide on insulin secretory pathwaysBALL, Andrew J; FLATT, Peter R; MCCLENAGHAN, Neville H et al.British journal of pharmacology. 2004, Vol 142, Num 2, pp 367-373, issn 0007-1188, 7 p.Article

Substrate specificity of the nateglinide/H⁺ cotransport system for phenolic acidsSAITO, Yoshitaka; ITAGAKI, Shirou; OTSUKA, Yukio et al.Journal of agricultural and food chemistry (Print). 2005, Vol 53, Num 15, pp 6100-6104, issn 0021-8561, 5 p.Article

Treatment of Patients over 64 years of age with type 2 diabetes: Experience from nateglinide pooled database retrospective analysisDEL PRATO, Stefano; HEINE, Robert J; KEILSON, Leonard et al.Diabetes care. 2003, Vol 26, Num 7, pp 2075-2080, issn 0149-5992, 6 p.Article

Determination of nateglinide in animal plasma by micellar electrokinetic chromatography and on-line sweeping techniqueHONGYUAN YAN; GENGLIANG YANG; FENGXIA QIAO et al.Journal of pharmaceutical and biomedical analysis. 2004, Vol 36, Num 1, pp 169-174, issn 0731-7085, 6 p.Article

Determination of the nateglinide polymorphic purity through DSCBRUNI, G; BERBENNI, V; MILANESE, C et al.Journal of pharmaceutical and biomedical analysis. 2011, Vol 54, Num 5, pp 1196-1199, issn 0731-7085, 4 p.Article

Insulin glargine in combination with nateglinide in people with type 2 diabetes : a randomized placebo-controlled trialDASHORA, U. K; SIBAL, L; ASHWELL, S. G et al.Diabetic medicine. 2007, Vol 24, Num 4, pp 344-349, issn 0742-3071, 6 p.Article

Effect of Piperine on Antihyperglycemic Activity and Pharmacokinetic Profile of NateglinideSAMA, V; NADIPELLI, M; YENUMULA, P et al.Arzneimittel-Forschung. 2012, Vol 62, Num 8, pp 384-388, issn 0004-4172, 5 p.Article

The effect of nateglinide taken with food on gastric emptying rates in healthy subjectsANDERSON, Denise; SHELLEY, Sarah; KELLETT, Norma et al.Clinical therapeutics. 2003, Vol 25, Num 6, pp 1722-1738, issn 0149-2918, 17 p.Article

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjectsNIEMI, Mikko; BACKMAN, Janne T; NEUVONEN, Mikko et al.British journal of clinical pharmacology. 2003, Vol 56, Num 4, pp 427-432, issn 0306-5251, 6 p.Article

Food-drug interaction between ferulic acid and nateglinide involving the Fluorescein/H⁺ cotransport systemITAGAKI, Shirou; KOBAYASHI, Yoko; OTSUKA, Yukio et al.Journal of agricultural and food chemistry (Print). 2005, Vol 53, Num 7, pp 2499-2502, issn 0021-8561, 4 p.Article

A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patientsSHIMABUKURO, M; HIGA, N; TAKASU, N et al.Diabetic medicine. 2004, Vol 21, Num 9, pp 983-986, issn 0742-3071, 4 p.Article

Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetesLINDSAY, J. R; MCKILLOP, A. M; MOONEY, M. H et al.Diabetes research and clinical practice. 2003, Vol 61, Num 3, pp 167-173, issn 0168-8227, 7 p.Article

New solid modifications of nateglinideBRUNI, G; BERBENNI, V; MILANESE, C et al.Journal of pharmaceutical and biomedical analysis. 2010, Vol 51, Num 5, pp 1054-1059, issn 0731-7085, 6 p.Article

Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditionsSCHATZ, H; SCHOPPEL, K; LEHWALDER, D et al.Experimental and clinical endocrinology & diabetes. 2003, Vol 111, Num 5, pp 262-266, issn 0947-7349, 5 p.Article

Repaglinide versus nateglinide monotherapy: A randomized, multicenter studyROSENSTOCK, Julio; HASSMAN, David R; MADDER, Robert D et al.Diabetes care. 2004, Vol 27, Num 6, pp 1265-1270, issn 0149-5992, 6 p.Article

Pharmacokinetics and metabolism of nateglinide in humansWEAVER, Margaret L; ORWIG, Barbara A; RODRIGUEZ, Lolita C et al.Drug metabolism and disposition. 2001, Vol 29, Num 4, pp 415-421, issn 0090-9556, 1Article

Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjectsLUZIO, Stephen D; ANDERSON, Denise M; OWENS, David R et al.The Journal of clinical endocrinology and metabolism. 2001, Vol 86, Num 10, pp 4874-4880, issn 0021-972XArticle